To Read The Complete Report With TOC Kindly Visit: http://www.researchmoz.us/pharmafocus-market-access-strategies-for-antibiotics-targeting-multidrug-resistant-gram-negative-bacteria-report.html
Summary
Since their discovery almost a century ago, antibiotics have revolutionized the global healthcare industry by ushering in an era of significantly reduced morbidity and mortality associated with often-lethal bacterial infections. However, the increasing threat posed by multidrug-resistant (MDR) bacteria, in particular gram-negative organisms, has cast a shadow over these remarkable public health achievements. GlobalDatas primary research indicates that this high level of unmet need has generated several opportunities for firms seeking access to the market in the US or 5EU. Public and private entities have also launched initiatives to make antibiotic R&D an attractive therapy area. GlobalData anticipates that a mixture of push, pull, and hybrid mechanisms will encourage progress through all stages of antibiotic development. Increased flexibility from the FDA and EMA is also expected to decrease barriers to entry for drugs targeting MDR gram-negative bacteria. GlobalData believes that a partnership approach, involving academia, small and medium enterprises, and Big Pharma, is the best strategy for companies hoping to leverage these incentives to gain access to the market.
Since their discovery almost a century ago, antibiotics have revolutionized the global healthcare industry by ushering in an era of significantly reduced morbidity and mortality associated with often-lethal bacterial infections. However, the increasing threat posed by multidrug-resistant (MDR) bacteria, in particular gram-negative organisms, has cast a shadow over these remarkable public health achievements. GlobalDatas primary research indicates that this high level of unmet need has generated several opportunities for firms seeking access to the market in the US or 5EU. Public and private entities have also launched initiatives to make antibiotic R&D an attractive therapy area. GlobalData anticipates that a mixture of push, pull, and hybrid mechanisms will encourage progress through all stages of antibiotic development. Increased flexibility from the FDA and EMA is also expected to decrease barriers to entry for drugs targeting MDR gram-negative bacteria. GlobalData believes that a partnership approach, involving academia, small and medium enterprises, and Big Pharma, is the best strategy for companies hoping to leverage these incentives to gain access to the market.
Highlights
Key Questions Answered
Key Questions Answered
- - What are the main unmet needs associated with treating drug-resistant gram-negative bacterial infections?
- - What opportunities can companies exploit to gain access to the US and 5EU markets?
- - What incentive mechanisms and programs can companies leverage to fund their antibiotic R&D?
- - How is the changing regulatory landscape at the FDA and EMA going to affect the review of antibiotics for MDR gram-negative bacterial infections?
- - What advantages does the public-private partnership approach to antibiotic R&D have over the traditional business plan for antibiotics?
Key Findings
- - The escalating need for therapies against MDR gram-negative bacteria has created opportunities that can be leveraged to enter the marketplace in both the US and 5EU.
- - Incentive initiatives, such as the Generating Antibiotics Incentives Now (GAIN) Act, are making antibiotics an attractive therapy area.
- - The FDA and EMA have both expressed and demonstrated a willingness to increase their flexibility regarding clinical trial design and endpoints.
- - The partnership approach to antibiotic R&D, which involves collaboration between academia, small and medium enterprises, and Big Pharma, is replacing the solo approach traditionally used by companies.
Scope
- - Overview of incentive mechanisms and programs designed to encourage antibiotic R&D, current regulatory trends, and the role of academia, small and medium enterprises and Big Pharma in bringing next-generation antibiotics to market.
- - Key topics covered include unmet needs, opportunities, and the emergence of public-private partnerships in the market for antibiotics targeting multidrug-resistant gram-negative bacteria.
- - Analysis of the key industry drivers, restraints and challenges in the US and 5EU. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- - Develop and design your market access strategy through a review of clinical and commercial unmet needs as well as regulatory trends related to gram-negative antibiotics.
- - Develop business strategies by understanding the trends shaping and driving the gram-negative antibiotics market in the US and 5EU.
- - Drive revenues by understanding the key trends and opportunities likely to impact the US and 5EU gram-negative antibiotics markets.
- - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Contact Us:
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976
Blog: http://researchmoz.blogspot.com
No comments:
Post a Comment